The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The collaboration will center on expanding access to Eastman’s Esmeri technology
Company to launch product after the expiry of semaglutide patent in India
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated